Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Medical Device

MicroPort MedBot’s Toumai Surgical Robot Wins NMPA Approval for Single-Hole Laparoscopy

Fineline Cube Feb 12, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that the National Medical Products Administration...

Company Deals

Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio

Fineline Cube Feb 11, 2025

Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...

Company Drug

J&J’s Rybrevant and Talvey Win Separate NMPA Approvals in China

Fineline Cube Feb 11, 2025

US pharma giant Johnson & Johnson (J&J, NYSE: JNJ) announced receiving marketing approvals from China’s...

Company Drug

Degron Therapeutics’ DEG6498 Receives FDA Clearance for Clinical Trials

Fineline Cube Feb 11, 2025

China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and...

Company Deals

Roche Transfers InterMune and Esbriet to Legacy Pharma in IP Deal

Fineline Cube Feb 11, 2025

Swiss pharma giant Roche (SWX: ROG) has transferred US-based InterMune, Inc., acquired for USD 8...

Company Drug

Bio-Thera Solutions’ BAT1006 Wins NMPA Approval for HER2+ Breast Cancer Trial

Fineline Cube Feb 11, 2025

China’s Bio-Thera Solutions Ltd (SHA: 688177) has received clinical trial approval from the National Medical...

Company Drug

China Resources Double-Crane Pharmaceutical Co., Ltd Receives NMPA Approval for Generic Purinethol

Fineline Cube Feb 11, 2025

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received marketing approval...

Company Drug

Henlius Biotech’s HLX99 Receives FDA Approval for ALS Clinical Study

Fineline Cube Feb 11, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Henlius Biotech Doses First Patient in HLX43 Phase II Study for Esophageal Cancer

Fineline Cube Feb 11, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a Phase II...

Company Drug

Bayer Files for Eylea 8 mg EMA Approval to Extend AMD, DME Treatment Intervals

Fineline Cube Feb 11, 2025

Bayer (ETR: BAYN) has submitted a marketing application to the European Medicines Agency (EMA) for...

Company Drug

Bristol-Myers Squibb’s Breyanzi Hits Primary Endpoint in Lymphoma Study

Fineline Cube Feb 11, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) reported positive results from the Phase II TRANSCEND FL study...

Company Drug

CSPC Pharmaceutical’s SYH2039 Wins FDA Clinical Approval for Advanced Tumors

Fineline Cube Feb 11, 2025

China’s CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration...

Company Drug

Boehringer Ingelheim’s Nerandomilast Hits Primary Endpoint in PPF Phase III Study

Fineline Cube Feb 11, 2025

German pharma giant Boehringer Ingelheim announced positive topline results from the Phase III FIBRONEER-ILD study...

Company Drug

CSPC Pharmaceutical’s Omalizumab Biosimilar Wins NMPA Approval for Allergic Asthma

Fineline Cube Feb 11, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received an additional indication approval from the...

Company Drug

Kelun-Biotech to Present SKB264/MK-2870 Data for Urothelial Carcinoma at ASCO-GU 2025

Fineline Cube Feb 11, 2025

China’s Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) will present efficacy and safety data from...

Company Drug

Sinopep-Allsino Wins NMPA Approval for Generic Liptruzet in China

Fineline Cube Feb 11, 2025

Jiangsu-based CDMO Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has received marketing approval from China’s National...

Company Deals

R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech

Fineline Cube Feb 11, 2025

Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD...

Company Deals

Bio-Thera Solutions Licenses BAT2506 to Intas Pharmaceuticals for US Market

Fineline Cube Feb 10, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that it has entered into a licensing agreement...

Company Drug

Changchun GeneScience’s GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials

Fineline Cube Feb 10, 2025

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another clinical trial approval...

Company Drug

CARsgen’s Allogeneic BCMA CAR-T Therapy Achieves sCR in First Patient

Fineline Cube Feb 10, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the first patient treated with its...

Posts pagination

1 … 152 153 154 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.